Skip to main content

MINI REVIEW article

Front. Oral. Health
Sec. Oral Cancers
Volume 5 - 2024 | doi: 10.3389/froh.2024.1426507
This article is part of the Research Topic Insights in Oral Cancers: 2023 View all 9 articles

Recent Advances in Minimally Invasive Biomarkers of OSCC: From generalized to personalized approach.

Provisionally accepted
Smriti Suri Smriti Suri Geeta S. Boora Geeta S. Boora Rajandeep Kaur Rajandeep Kaur Anshika Chauhan Anshika Chauhan SUSHMITA GHOSHAL SUSHMITA GHOSHAL *Arnab Pal Arnab Pal *
  • Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

The final, formatted version of the article will be published soon.

    Oral cancer is the 6th most common type of cancer worldwide, and oral squamous cell carcinoma (OSCC) accounts for >90% of oral cancers. It is a major health problem, particularly in low- and middle-income countries (LMICs), due to both its high incidence and significant mortality and morbidity. Despite being a global burden, and even with the significant advancement in the management of OSCC, the overall outcome of the disease is still abysmal. With the advent of time, advanced diagnostic and treatment approaches have come into practice, but the burden of the disease has not improved significantly. Major reasons attributed to the poor outcome are delay in diagnosis, locoregional recurrence and resistance to the currently available treatment regimen. In this review, we have highlighted the existing challenges in the diagnosis and have emphasized the advancements in minimally invasive biomarkers. Additionally, the importance of collaborative multidimensional approaches involving clinicians and researchers has been discussed, as well as the need to redefine and establish better utility and management of existing diagnostic and treatment protocols along with the minimally invasive/non-invasive biomarkers.

    Keywords: Oral squamous cell carcinoma (OSCC), Minimally invasive biomarker, Proteomic biomarker, Genomic biomarkers, Circulating tumour cell (CTC), circulating tumour DNA (ctDNA)

    Received: 01 May 2024; Accepted: 16 Jul 2024.

    Copyright: © 2024 Suri, Boora, Kaur, Chauhan, GHOSHAL and Pal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    SUSHMITA GHOSHAL, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    Arnab Pal, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.